Given these observations, it has been
hypothesized that interventions that further lower
proteinuria will further reduce the risk of progression.
6 Combination therapy with an angiotensin-
converting–enzyme (ACE) inhibitor and an
angiotensin II–receptor blocker (ARB) results in
a greater decrease in proteinuria than does monotherapy
with either type of agent.7